Bonesupport Holding AB (publ) announced its financial results for the second quarter of 2026 on July 16, 2026. The Swedish orthobiologics company reported a GAAP EPS of SEK 1.23, a significant achievement that underscores its transition to profitability. Quarterly revenue totaled SEK 355.7 million, reflecting continued commercial execution for its CERAMENT bone graft substitute platform. These figures represent a substantial improvement over the company's performance in the same period last year.
Context — [why this matters now]
The Q2 2026 results mark a critical inflection point for Bonesupport. The company reported a GAAP net loss of SEK 12.7 million in the second quarter of 2025. The shift to a GAAP profit of approximately SEK 43 million this quarter demonstrates the scalability of its commercial model. This profitability milestone arrives as the global orthobiologics market is projected to grow at a compound annual growth rate of 5.8% through 2030.
Investor focus on profitable growth has intensified in the current macroeconomic environment. The STOXX Europe 600 Health Care index has underperformed the broader market year-to-date, increasing pressure on medtech firms to demonstrate clear paths to earnings. Bonesupport’s ability to deliver GAAP profitability ahead of many peers provides a key differentiator. The catalyst for this quarter's strong performance was accelerated adoption in key European markets and sustained market share gains in the United States.
CERAMENT’s unique value proposition as an antibiotic-eluting bone graft addresses a significant unmet need in managing bone infections. The clinical data supporting its use in revision arthroplasty and trauma surgery has driven formulary approvals. This has directly contributed to the consistent double-digit revenue growth observed over the past six consecutive quarters.
Data — [what the numbers show]
The second quarter revenue of SEK 355.7 million represents a 28% increase compared to the SEK 278.1 million reported in Q2 2025. Sequentially, revenue grew 9% from the first quarter’s SEK 326.4 million. The GAAP EPS of SEK 1.23 is a dramatic improvement from the loss per share of SEK 0.36 in the prior-year period.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|
| Revenue (SEK M) | 355.7 | 278.1 | +28% |
| GAAP EPS (SEK) | 1.23 | -0.36 | N/M |
| Gross Margin | 87.5% | 86.1% | +140 bps |
The gross margin expanded by 140 basis points to 87.5%, indicating improved manufacturing efficiency and favorable product mix. This margin significantly exceeds the sector median for small-to-mid-cap medical device companies, which typically ranges from 65% to 75%. The company’s market capitalization increased by approximately SEK 1.2 billion in pre-market trading following the announcement. Sales growth in the US, its largest market, outpaced the overall company growth rate, coming in at 32% year-over-year.
Analysis — [what it means for markets / sectors / tickers]
Bonesupport’s strong results are a positive signal for the orthobiologics subsector, particularly for companies with differentiated technology platforms. Peer companies like SEMAF (Semafon AB) and STU (Stryker Corporation) may see increased investor scrutiny on their own growth and margin profiles. The results could also benefit suppliers of synthetic bone graft materials, as they validate the market's acceptance of advanced biomaterials over traditional autografts.
The primary risk to the thesis is the concentration of Bonesupport’s product portfolio. While CERAMENT’s success is driving growth, the company remains heavily reliant on a single product line. Any regulatory setback or competitive product launch could materially impact future revenue streams. Another consideration is the sustainability of pricing in the US market, where reimbursement pressures are a constant headwind.
Institutional flow data suggests that long-only healthcare funds have been accumulating positions in profitable medtech names. Bonesupport’s entry into GAAP profitability likely places it on the radar of a broader set of investors who mandate positive earnings as a screening criterion. Short interest had been elevated ahead of the report, around 5% of the float, potentially setting the stage for a short squeeze if bullish momentum continues.
Outlook — [what to watch next]
The next significant catalyst for Bonesupport is the full earnings report and conference call, scheduled for July 23, 2026. Management’s commentary on full-year 2026 guidance will be critical; investors will watch for any upward revision to the current revenue forecast of SEK 1.35-1.4 billion. Key levels to monitor for the share price include the 50-day moving average, currently around SEK 245, as near-term support.
Regulatory milestones provide another watchpoint. The company has a pre-market approval application pending with the US Food and Drug Administration for a new CERAMENT indication. A decision is expected in the fourth quarter of 2026. Approval would unlock an additional addressable market estimated at over $500 million annually. Investors should also monitor quarterly prescription data from key European markets like Germany and the UK for signs of sustained volume growth. If prescription trends decelerate below 15% quarterly growth, it could signal market saturation.
Frequently Asked Questions
How does Bonesupport's profitability compare to other orthobiologics companies?
Bonesupport’s transition to GAAP profitability is notable within the orthobiologics peer group. Many smaller-cap companies in the space, such as Bioventus Inc., have struggled to achieve consistent bottom-line results. Bonesupport’s 87.5% gross margin is exceptionally high, driven by the proprietary nature of its injectable ceramic scaffold. This margin profile provides a significant advantage in funding future research and commercial expansion without excessive dilution.
What is the main driver of Bonesupport's revenue growth?
The primary growth driver is the commercial adoption of CERAMENT® G and CERAMENT® V in the United States for the treatment of bone infections and void filling. US sales grew 32% year-over-year, accounting for over 60% of total revenue. The sales force has successfully penetrated the hospital and ambulatory surgery center markets, emphasizing the product's clinical benefits in reducing revision surgery rates.
What are the risks associated with investing in Bonesupport?
The key investment risks include product concentration, as CERAMENT comprises nearly all revenue. Regulatory changes in healthcare reimbursement, particularly from US Medicare and private insurers, could pressure pricing. Competition is also intensifying from large medtech firms developing their own advanced bone graft substitutes. Finally, as a Swedish company listed on Nasdaq Stockholm, US investors face currency risk related to the SEK/USD exchange rate.
Bottom Line
Bonesupport’s GAAP profitability marks a fundamental shift in its investment profile.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
